Published in J Immunol on May 01, 1991
Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature (1992) 16.46
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A (1992) 4.94
Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med (1998) 3.56
Transforming growth factor-beta: recent progress and new challenges. J Cell Biol (1992) 3.18
Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med (1994) 2.86
Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med (1994) 2.70
Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med (1992) 2.27
Theiler's virus infection: a model for multiple sclerosis. Clin Microbiol Rev (2004) 1.92
The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease. J Exp Med (1993) 1.80
Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci U S A (1993) 1.64
Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol (1993) 1.64
Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med (1997) 1.55
Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med (1993) 1.52
TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 1.48
Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med (1994) 1.43
Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest (1996) 1.42
One systemic administration of transforming growth factor-beta 1 reverses age- or glucocorticoid-impaired wound healing. J Clin Invest (1993) 1.42
Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci U S A (1996) 1.38
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest (1998) 1.36
Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am J Pathol (1995) 1.19
Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Med Genet (2008) 1.11
Subsets of transgenic T cells that recognize CD1 induce or prevent murine lupus: role of cytokines. J Exp Med (1998) 1.11
Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol (1991) 1.07
Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest (1998) 1.03
Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J Clin Invest (2000) 1.02
Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-beta1. J Clin Invest (1998) 1.01
Endogenous altered peptide ligands can affect peripheral T cell responses. J Exp Med (1996) 1.01
Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J Clin Invest (1998) 1.00
Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation (2008) 0.99
Medical applications of transforming growth factor-beta. Clin Med Res (2003) 0.97
Transforming growth factor beta in Alzheimer's disease. Clin Diagn Lab Immunol (1994) 0.96
Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol (2009) 0.94
Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. Proc Natl Acad Sci U S A (1998) 0.93
Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course. Am J Pathol (1996) 0.93
Neutralization of transforming growth factor-beta 1 in a mouse model of immune-induced lung fibrosis. Immunology (1994) 0.92
Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol (1994) 0.92
Amniotic epithelial cells from the human placenta potently suppress a mouse model of multiple sclerosis. PLoS One (2012) 0.91
Expression of transforming growth factor-beta 1 and interleukin-1 beta mRNA in rat brain following transient forebrain ischemia. Acta Neuropathol (1993) 0.91
TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10. J Immunol (2010) 0.89
Experimental autoimmune uveoretinitis (EAU) versus experimental allergic encephalomyelitis (EAE): a comparison of T cell-mediated mechanisms. Clin Exp Immunol (1992) 0.88
Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. Am J Pathol (2000) 0.88
Immunophenotypic analysis of infiltrating leukocytes and microglia in an experimental rat glioma. Acta Neuropathol (1992) 0.88
The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) up-regulation and increased prostaglandin E2 (PGE2) production. Clin Exp Immunol (2000) 0.88
Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease. Immunology (1994) 0.86
MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). BMC Immunol (2013) 0.86
TGFβ in T cell biology and tumor immunity: Angel or devil? Cytokine Growth Factor Rev (2014) 0.85
Expression of TGF-beta in attenuated Salmonella typhimurium: oral administration leads to the reduction of inflammation, IL-2 and IFN-gamma, but enhancement of IL-10, in carrageenin-induced oedema in mice. Immunology (1995) 0.84
Specific binding of endocrine transforming growth factor-beta 1 to vascular endothelium. J Clin Invest (1995) 0.83
Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN. Immunology (1994) 0.83
TGFβ signaling regulates the timing of CNS myelination by modulating oligodendrocyte progenitor cell cycle exit through SMAD3/4/FoxO1/Sp1. J Neurosci (2014) 0.83
Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: Implications for multiple sclerosis. Brain Behav Immun (2014) 0.80
Vitamin D receptor agonists: suitable candidates as novel therapeutic options in autoimmune inflammatory myopathy. Biomed Res Int (2014) 0.80
TGF-β signaling initiated in dendritic cells instructs suppressive effects on Th17 differentiation at the site of neuroinflammation. PLoS One (2014) 0.79
Cytokine mRNA profiles in mononuclear cells in acute aseptic meningoencephalitis. Infect Immun (1995) 0.79
Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update. West J Med (1992) 0.79
Transgenic models for cytokine-induced neurological disease. Biochim Biophys Acta (2009) 0.79
Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol (2010) 0.79
Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor. J Clin Invest (1994) 0.78
Morphogens and blood-brain barrier function in health and disease. Tissue Barriers (2015) 0.78
Production, regulation and role of nitric oxide in glial cells. Mediators Inflamm (1998) 0.77
Regulatory T-cell vaccination independent of auto-antigen. Exp Mol Med (2014) 0.77
Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis. BMC Neurosci (2012) 0.76
MicroRNAs targeting TGFβ signalling underlie the regulatory T cell defect in multiple sclerosis. Brain (2016) 0.76
Cytokines and autoimmunity. Clin Exp Immunol (1994) 0.76
Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. Transplant Proc (1991) 0.75
Oral Delivery of Particulate Transforming Growth Factor Beta 1 and All-Trans Retinoic Acid Reduces Gut Inflammation in Murine Models of Inflammatory Bowel Disease. J Crohns Colitis (2015) 0.75
Activation of human B cells negatively regulates TGF-β1 production. J Neuroinflammation (2017) 0.75
Potential of targeting TGF-β for organ transplant patients. Future Med Chem (2013) 0.75
Prevention of experimental autoimmune encephalomyelitis in DA rats by grafting primary skin fibroblasts engineered to express transforming growth factor-beta1. Clin Exp Immunol (2004) 0.75
TGFβ regulates persistent neuroinflammation by controlling Th1 polarization and ROS production via monocyte-derived dendritic cells. Glia (2016) 0.75
TGF-β regulation of encephalitogenic and regulatory T cells in multiple sclerosis. Eur J Immunol (2017) 0.75
Models for longitudinal data: a generalized estimating equation approach. Biometrics (1988) 27.90
Two pleiotropic classes of daf-2 mutation affect larval arrest, adult behavior, reproduction and longevity in Caenorhabditis elegans. Genetics (1998) 5.37
Interacting genes in nematode dauer larva formation. Nature (1981) 5.21
Genes that regulate both development and longevity in Caenorhabditis elegans. Genetics (1995) 5.09
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Control of C. elegans larval development by neuronal expression of a TGF-beta homolog. Science (1996) 4.23
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol (1988) 3.63
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larva development. Nature (1993) 3.45
Sensory control of dauer larva formation in Caenorhabditis elegans. J Comp Neurol (1981) 3.41
Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med (2000) 3.20
daf-1, a C. elegans gene controlling dauer larva development, encodes a novel receptor protein kinase. Cell (1990) 3.16
Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol (1981) 3.15
Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA (2000) 3.13
T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science (1994) 3.00
Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science (1983) 2.91
Observations on viral demyelinating encephalomyelitis. Canine distemper. Lab Invest (1972) 2.88
Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol (1975) 2.86
Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med (1994) 2.70
The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol (1995) 2.57
Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus. Nature (1974) 2.55
Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med (1997) 2.51
Ataxia-telangiectasia. Medicine (Baltimore) (1972) 2.50
Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst (2001) 2.43
Late complications of immune deviation therapy in a nonhuman primate. Science (1996) 2.30
Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature (1988) 2.27
Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol (2001) 2.27
Electron microscopic observations on the cerebellar cortex in kuru. J Neurol Sci (1969) 2.14
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol (1990) 2.07
dpy-13: a nematode collagen gene that affects body shape. Cell (1988) 2.05
Homing to central nervous system vasculature by antigen-specific lymphocytes. I. Localization of 14C-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitis. Lab Invest (1990) 2.03
Further studies on the specificity of presumed immune associations of myasthenia gravis and consideration of possible pathogenic implications. Ann N Y Acad Sci (1966) 2.02
Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest (1991) 2.01
Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol (1991) 2.00
Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature (1984) 1.95
Senile plaques and cerebral amyloidosis in aged dogs. A histochemical and ultrastructural study. Lab Invest (1970) 1.93
GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron (1996) 1.91
Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol (1995) 1.91
Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis. Nature (1993) 1.89
Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol (1991) 1.84
Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest (1981) 1.84
A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med (1991) 1.84
Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest (1984) 1.83
Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol (2001) 1.78
Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol (1999) 1.77
Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol (1995) 1.76
An ultrastructural study of experimental demyelination and remyelination. I. Acute experimental allergic encephalomyelitis in the peripheral nervous system. Lab Invest (1969) 1.73
Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol (1991) 1.73
Multiple sclerosis (first of two parts). N Engl J Med (1982) 1.72
Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol (1990) 1.71
Fine structure of the Caenorhabditis elegans secretory-excretory system. J Ultrastruct Res (1983) 1.67
Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Invest (1990) 1.67
Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci U S A (1991) 1.65
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol (1996) 1.64
Hormone replacement therapy and colorectal adenoma recurrence among women in the Polyp Prevention Trial. J Natl Cancer Inst (2001) 1.62
Experimental allergic encephalomyelitis: enhancement of cell-mediated transfer by concanavalin A. J Immunol (1977) 1.58
Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol (1993) 1.58
On the presence of Ia-positive endothelial cells and astrocytes in multiple sclerosis lesions and its relevance to antigen presentation. J Neuroimmunol (1985) 1.56
Developmental alterations in sensory neuroanatomy of the Caenorhabditis elegans dauer larva. J Comp Neurol (1983) 1.55
Axons: isolation from mammalian central nervous system. Science (1972) 1.55
Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med (1996) 1.53
On the development of CNS lesions in natural canine distemper encephalomyelitis. J Neurol Sci (1976) 1.53
Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell Immunol (1985) 1.52
Impaired lymphocyte transformation in ataxia-telangiectasia in part due to a plasma inhibitory factor. J Immunol (1969) 1.51
Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol (1992) 1.50
Temperature-sensitive mutants of reovirus type 3: defects in viral maturation as studied by immunofluorescence and electron microscopy. Virology (1971) 1.50
Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol (1983) 1.45
Chronic experimental allergic encephalomyelitis in inbred guinea pigs. An ultrastructural study. Lab Invest (1974) 1.44
Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst (2001) 1.43
Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int Immunol (1992) 1.43
Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuroimmunol (1988) 1.42
Ultrastructure of measles virus in cultures of hamster cerebellum. J Virol (1969) 1.42
Immunoglobulin A production in ataxia telangiectasia. Science (1965) 1.41
Invasion of neurones in vitro by non immune lymphocytes. An electron microscopic study. Br J Exp Pathol (1968) 1.41
Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol (1992) 1.40
Progressive demyelination and reparative phenomena in chronic experimental allergic encephalomyelitis. J Neuropathol Exp Neurol (1975) 1.40
Rapid degradation restricts measles virus matrix protein expression in a subacute sclerosing panencephalitis cell line. Proc Natl Acad Sci U S A (1986) 1.38
An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med (1970) 1.38
Immunoglobulin metabolism in ataxia telangiectasia. J Clin Invest (1968) 1.38
Reovirus type 3 encephalitis--a virologic and ultrastructural study. J Neuropathol Exp Neurol (1973) 1.36
Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today (1994) 1.35
Induction of experimental allergic encephalomyelitis in PL/J and (SJL/J x PL/J)F1 mice by myelin basic protein and its peptides: localization of a second encephalitogenic determinant. J Immunol (1983) 1.35